Articles tagged with Catalytic Antibodies
CAR-T cell therapy, a regenerative immunotherapy, has shown promise in treating blood cancers but struggles with T-cell exhaustion. Researchers have discovered that overproduction of the IL-4 protein causes this exhaustion and used CRISPR gene-editing technology to remove it, improving CAR-T cell therapy outcomes.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
Researchers at UVA Health discovered a potential explanation for long COVID symptoms by identifying 'abzymes' that act like enzymes regulating important bodily functions. This discovery could lead to new treatments targeting these rogue antibodies to alleviate acute effects of COVID-19 and its complications.
Researchers at UT Medical School have pinpointed the Achilles heel of HIV in the envelope protein gp120, a region essential for viral attachment to host cells. Engineered antibodies with enzymatic activity, or abzymes, can attack this weak spot, offering new hope for therapeutic intervention and prevention.
A new urine test developed by Irish scientists can detect the 'date rape drug' Rohypnol up to a week after its use. The test uses antibodies and enzymes to identify the metabolite of Rohypnol, improving detection beyond existing antibody tests.
Researchers create first commercially available catalytic antibody, which can catalyze aldol reactions with broad substrate range. This breakthrough addresses long-standing question of protein-catalyst efficiency.
Eukarion's antibody lipidation technology successfully blocks HIV-1 viral replication in human lymphocytic cells by targeting the Tat protein. The modified anti-Tat antibody is effective against laboratory and patient-strain viruses, offering new potential for cell-specific AIDS immunotherapies.